Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension

Journal of Human Hypertension

Volumn 25, Issue 5, 2011, Pages 304-310

  Ho, L Y ^a   Siu, C W ^a,b   Yue, W S ^a   Lau, C P ^a   Lip, G Y ^c   Tse, H F ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

AF; anti hypertensive therapy; anticoagulation

Indexed keywords

ANTITHROMBOCYTIC AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHINESE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INDEPENDENT VARIABLE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT; PATIENT SAFETY; PREDICTOR VARIABLE; SMOKING; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE;

EID: 79954982790     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.57     Document Type: Article

References (21)

1. National Collaborating Centre for Chronic Conditions\National Government Agency. Atrial fibrillation: National clinical guideline for management in primary and second-ary care. Royal College of Physicians: London (UK), 2006.
2. Lip GY, Lim HS. Atrial fibrillation and stroke preven-tion. Lancet Neurol 2007; 6(11): 981-993.
3. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840-844.
4. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98(5): 476-484.
5. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. Neurology 1993; 43(1): 32-36. (Pubitemid 23035353)
6. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. NEngl J Med 2003; 349(11): 1019-1026. (Pubitemid 37087616)
7. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114(7): e257-e354. (Pubitemid 44252297)
8. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospec-tive collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348(9025): 423-428. (Pubitemid 26267872)
9. Mok V, Wong KS, Lam WM, Poon WS, Kay R. Warfarin associated intracerebral hemorrhage occurs with lower intensification of anticoagulation in Chinese. Neurol J Southeast Asia 2001; 6: 107-111.
10. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med (Tokyo, Japan) 2001; 40(12): 1183-1188. (Pubitemid 34110494)
11. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285(26): 1441-1446.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifica-tion schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22): 2864-2870. (Pubitemid 32537350)
13. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S et al. Comparison of outcomes among patients randomized to warfarin therapy according to antic-oagulant control: results from III SPORTIF and V. Arch Intern Med 2007; 167(3): 239-245.
14. Fihn SD, McDonell M, Martin D, HenikoffJ, Vermes D, Kent D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118(7): 511-520. (Pubitemid 23085793)
15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69(3): 236-239. (Pubitemid 23069000)
16. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation (SPAF-III) study). J Am Soc Echocardiogr 1999; 12(12): 1088-1096.
17. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrilla-tion (SPAF-III) study). J Am Soc Echocardiogr 1999; 12(12): 1080-1087.
18. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG Transesophageal echocardio-graphic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31(7): 1622-1626. (Pubitemid 28273307)
19. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007; 28(6): 752-759. (Pubitemid 46439230)
20. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293(6): 690-698.
21. Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recur-rence in stroke patients with atrial fibrillation? Stroke 2001; 32(12): 2828-2832. (Pubitemid 33134473)